Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis
Within the current reimbursement context in China, once-weekly icodec is a dominant strategy compared with degludec, offering greater health benefits at a lower cost for patients with type 2 diabetes and generating potential annual savings.
Authors
- Luying Zhang (ORCID: https://orcid.org/0000-0002-1304-4550)
- Xichen Tong
- Lei Zhang
- Yawen Zhang
Institutions
- Fudan University (CN)
- Wuhan University (CN)
- Wuhan Donghu University (CN)
- Novo Nordisk (Switzerland) (CH)
- Novo Nordisk (Italy) (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1111/dom.70435
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 61.46